AuroMedics Pharma Recalls Ampicillin and Sulbactam for Injection
The company is voluntarily recalling product because of glass particles found in vials.
On Jan. 3, 2018, AuroMedics Pharma LLC announced it was voluntarily recalling lot AFO l 17001-A of Ampicillin and Sulbactam for Injection USP, 1.5 g (equivalent to 1 g ampicillin as the sodium salt plus 0.5 g Sulbactam as the sodium salt) in a Single-Dose vial, to the hospital level. The product is being recalled after glass particulates were found in vials.
According to the company, if glass is present in the intravenous drug and is administered, reactions from local irritation and swelling to more serious conditions such as blockage and clotting in blood vessels may occur. No adverse events have been reported as of January 3.
The affected lot has an expiration date of December 2018 and is packaged in a carton containing 10 vials, NDC: 55150-116-20. The lot was shipped to wholesalers and/or hospitals nationwide on Feb. 9, 2017.
Ampicillin and Sulbactam for Injection is used to treat infections “due to susceptible strains of designated microorganism in skin and skin structure infections, intraÂabdominal infections, and gynecological infections in adults and for treatment of skin and skin structure infection in pediatric patient one year and older,” according to a press release.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
